Trial Profile

A FIH study of EKZ 102.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EKZ 102 (Primary)
Indications Amyotrophic lateral sclerosis; Neurodegenerative disorders
Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

09 Oct 2025 According to Eikonizo Therapeutics Media Release, EKZ-102 is on track to enter phase 1 clinical trials in 2026.
13 Dec 2024 New trial record
10 Dec 2024 According to Eikonizo Therapeutics Media Release, company is planning a first-in-human clinical study planned in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com